Pay vs Performance Disclosure - USD ($)
|
5 Months Ended |
7 Months Ended |
12 Months Ended |
Jun. 30, 2024 |
Jan. 31, 2024 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2021 |
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure, Table |
|
|
|
Pay vs. Performance
As required by SEC rules, we are providing the
following information about the relationship between executive compensation actually paid (as defined by SEC rules) and certain
financial performance measures. For information about how our Compensation Committee seeks to align executive compensation with
the Company’s performance, see “Compensation discussion and analysis.” The amounts in the table below are calculated
in accordance with SEC rules and do not represent amounts actually earned or realized by our NEOs.
| |
|
Summary
Compensation
Table Total for |
|
|
Compensation
actually paid to |
|
|
Summary
Compensation
Table Total for |
|
|
Compensation
actually paid to |
|
|
Average
Summary
Compensation
Table Total |
|
|
Average
Compensation
actually paid |
|
|
Value of Initial Fixed
$100 Investment
based on: |
|
|
|
|
|
Company-
selected
Measure |
Fiscal
Year |
|
CEO(1)(2)
Mr. Kelderman |
|
|
CEO(1)(2)(3)
Mr. Kelderman |
|
|
CEO(1)
Mr. Kummeth |
|
|
CEO(1)(3)
Mr. Kummeth |
|
|
for
Non-PEO
NEOs(2)
|
|
|
to Non-PEO
NEOs(2)
|
|
|
Company
TSR |
|
|
Peer
Group
TSR(4)
|
|
|
Net
Income(5)
|
|
|
(Organic
Revenue)(6)
|
| 2024 |
|
$ |
6,852,495 |
|
|
$ |
3,403,621 |
|
|
$ |
6,792,945 |
|
|
$ |
4,821,823 |
|
|
$ |
12,300,286 |
|
|
$ |
4,147,638 |
|
|
$ |
110.17 |
|
|
$ |
131.47 |
|
|
$ |
168,105,000 |
|
|
$ |
1,141,700 |
| 2023 |
|
|
0 |
|
|
|
0 |
|
|
|
30,584,644 |
|
|
|
4,684,176 |
|
|
|
2,258,387 |
|
|
|
2,424,680 |
|
|
|
124.96 |
|
|
|
126.72 |
|
|
|
285,442,000 |
|
|
|
1,134,700 |
| 2022 |
|
|
0 |
|
|
|
0 |
|
|
|
15,370,549 |
|
|
|
(6,349,624 |
) |
|
|
3,223,063 |
|
|
|
(2,680,481 |
) |
|
|
132.17 |
|
|
|
129.72 |
|
|
|
263,099,000 |
|
|
|
1,113,600 |
| 2021 |
|
|
0 |
|
|
|
0 |
|
|
|
15,889,896 |
|
|
|
105,676,083 |
|
|
|
4,950,600 |
|
|
|
26,444,391 |
|
|
|
171.17 |
|
|
|
147.61 |
|
|
|
139,585,000 |
|
|
|
915,900 |
| (1) |
The Company had
two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer
and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer
effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO
for the full fiscal years 2021 through 2023. |
| (2) |
For fiscal year
2024, Mr. Kelderman held his position as President, Diagnostics and Genomics prior to assuming the position of CEO on February
1, 2024. Therefore, any compensation granted or vested prior to assuming the position of CEO is included in the average non-PEO
NEO compensation for fiscal year 2024. |
| (3) |
Amounts reported
in this column and in the table below represent the amount of “Compensation Actually Paid” or “CAP”
as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the individual(s)
during the applicable fiscal year. The following table summarizes the adjustments made to total compensation in accordance
with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation
Actually Paid”. |
| (4) |
The Peer Group TSR in
the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the
company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year
2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30,
2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance
is not necessarily indicative of future stock performance. |
| (5) |
Net income represents “Net earnings,
including noncontrolling interest” as reported in the Company’s Annual Report on Form 10-K. |
| (6) |
Sales shown reflect organic revenue as calculated
for purposes of our executive compensation program for the applicable reporting year. Refer to Appendix A for a reconciliation
between GAAP and non-GAAP measures. |
| (1) |
The Company had
two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer
and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer
effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO
for the full fiscal years 2021 through 2023. |
| (2) |
For fiscal year
2024, Mr. Kelderman held his position as President, Diagnostics and Genomics prior to assuming the position of CEO on February
1, 2024. Therefore, any compensation granted or vested prior to assuming the position of CEO is included in the average non-PEO
NEO compensation for fiscal year 2024. |
| (3) |
Amounts reported
in this column and in the table below represent the amount of “Compensation Actually Paid” or “CAP”
as computed per SEC rules. These amounts do not reflect the actual amount of compensation earned by or paid to the individual(s)
during the applicable fiscal year. The following table summarizes the adjustments made to total compensation in accordance
with Item 402(v) of Regulation S-K in order to determine the compensation amounts shown in the table above as being “Compensation
Actually Paid”. |
| |
For this purpose,
the fair value of equity awards was determined pursuant to the FASB ASC Topic 718. Assumptions used in the calculation of
the fair value are consistent with the stock option valuation model used to determine the amounts reported in the Company’s
audited financial statements, included in the Company’s Annual Report on Form 10-K. |
| |
The fair value of
unvested time-based share awards, including restricted stock awards and restricted stock units, as well as the valuation of
all share-based awards upon vesting, is based upon the closing price for a share of Bio-Techne common stock for the applicable
date of measurement. The fair value of unvested performance share awards is based upon the probable outcome of the applicable
performance conditions at the time of measurement. The fair value of unvested options, and the fair value received upon the
vesting of stock options, is based upon the Black-Scholes option-pricing model as of the date of measurement, consistent with
the stock option valuation model used to determine amounts reported in the Company’s Annual Report on Form 10-K. |
| |
|
|
FY24 |
|
FY23 |
|
|
FY22 |
|
FY21 |
|
| |
|
|
CEO
Mr. Kelderman |
|
|
CEO
Mr. Kummeth |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
| |
Total
from Summary Compensation Table(i)
|
|
|
6,852,495 |
|
|
|
6,792,945 |
|
|
|
12,300,286 |
|
|
|
30,584,644 |
|
|
|
2,258,387 |
|
|
|
15,370,549 |
|
|
|
3,223,063 |
|
|
|
15,889,896 |
|
|
|
4,950,600 |
|
| |
Subtract:
Grant date fair value of option and stock awards granted in the fiscal year(ii) |
|
|
(5,793,851 |
) |
|
|
(5,000,028 |
) |
|
|
(9,849,980 |
) |
|
|
(29,325,210 |
) |
|
|
(850,075 |
) |
|
|
(10,299,362 |
) |
|
|
(949,840 |
) |
|
|
(11,199,803 |
|
|
|
(1,722,395 |
) |
| |
Add:
Fair value at fiscal year end of outstanding and unvested option and stock awards granted in the fiscal year(iii) |
|
|
2,344,977 |
|
|
|
4,234,157 |
|
|
|
2,565,518 |
|
|
|
4,318,227 |
(11) |
|
|
1,382,025 |
|
|
|
6,472,546 |
|
|
|
1,106,688 |
|
|
|
30,362,017 |
|
|
|
10,602,750 |
|
| |
Add/Subtract:
Year-over-Year change in fair value of outstanding and unvested option and stock awards granted in prior fiscal years(iv) |
|
|
— |
|
|
|
(1,241,718 |
) |
|
|
(847,318 |
) |
|
|
(6,132,401 |
) |
|
|
(877,492 |
) |
|
|
(22,021,635 |
) |
|
|
(5,636,997 |
) |
|
|
64,935,446 |
|
|
|
11,789,651 |
|
| |
Add:
Vesting date fair value of option and stock awards granted and vesting during the fiscal year(v) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| |
Add/Subtract:
Change as of the vesting date (from the end of the prior fiscal year) in fair value of option and stock awards granted in any prior
fiscal year for which vesting conditions were satisfied during the fiscal year, less the fair value (as of end of prior fiscal year)
of prior year awards that failed to vest(vi) |
|
|
— |
|
|
|
36,468 |
|
|
|
(20,867 |
) |
|
|
5,238,918 |
|
|
|
633,346 |
|
|
|
4,128,278 |
|
|
|
469,566 |
|
|
|
5,688,527 |
|
|
|
823,785 |
|
| |
|
|
FY24 |
|
FY23 |
|
|
FY22 |
|
FY21 |
|
| |
|
|
CEO
Mr. Kelderman |
|
|
CEO
Mr. Kummeth |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
| |
Subtract:
Awards granted in prior years that did not meet the applicable vesting conditions during the fiscal year(vii) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(121,511 |
) |
|
|
— |
|
|
|
(892,961 |
) |
|
|
— |
|
|
|
— |
|
| |
Compensation Actually
Paid |
|
|
3,403,621 |
|
|
|
4,821,823 |
|
|
|
4,147,638 |
|
|
|
4,684,176 |
|
|
|
2,424,680 |
|
|
|
(6,349,624 |
) |
|
|
(2,680,481 |
) |
|
|
105,676,083 |
|
|
|
26,444,391 |
|
| |
(i) |
Represents Total
Compensation as reported in the Summary Compensation Table for each fiscal year |
| |
(ii) |
Represents Stock
Awards and Option Awards from the Summary Compensation Table for each fiscal year |
| |
(iii) |
Represents the aggregate
fair value as of each fiscal year-end of outstanding and unvested option and stock awards granted during the covered fiscal
year, computed in accordance with the Company’s methodology used for financial reporting purposes. |
| |
(iv) |
Represents the aggregate
change in fair value during each fiscal year of the outstanding and unvested option and stock awards granted in prior fiscal
years and held as of the last day of the covered fiscal year, computed in accordance with the Company’s methodology
used for financial reporting purposes. |
| |
(v) |
Represents the aggregate
fair value as of the vesting date of for each option and stock award that was granted and vested during the covered fiscal
year, computed in accordance with the Company’s methodology used for financial reporting purposes. |
| |
(vi) |
Represents the aggregate
change in fair value, measured from the prior fiscal year-end to the vesting date, of each option and stock award that was
granted in a prior fiscal year and which vested during the covered fiscal year, computed in accordance with the Company’s
methodology used for financial reporting purposes. |
| |
(vii) |
Represents the fair
value as of the end of the prior fiscal year of option and stock awards that were granted in any prior fiscal year that failed
to meet the applicable vesting conditions during the covered fiscal year, computed in accordance with the Company’s
methodology used for financial reporting purposes. These options and stock awards relate to retirements during the applicable
fiscal year. |
| |
|
|
| (4) |
The Peer Group TSR in
the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the
company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year
2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30,
2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance
is not necessarily indicative of future stock performance. |
| (5) |
Net income represents “Net earnings,
including noncontrolling interest” as reported in the Company’s Annual Report on Form 10-K. |
| (6) |
Sales shown reflect organic revenue as calculated
for purposes of our executive compensation program for the applicable reporting year. Refer to Appendix A for a reconciliation
between GAAP and non-GAAP measures. |
| (7) |
The non-PEO NEOs during fiscal year 2024
were James Hippel, William Geist, Kim Kelderman (until February 1, 2024), Shane Bohnen, and Matthew McManus (from January
1, 2024 until the end of the fiscal year). |
| (8) |
The non-PEO NEOs during fiscal year 2023
were James Hippel, William Geist, Kim Kelderman, Shane Bohnen, and Brenda Furlow. |
| (9) |
The non-PEO NEOs during fiscal year 2022
were James Hippel, William Geist, Kim Kelderman, Brenda Furlow, and David Eansor. |
| (10) |
The non-PEO NEOs during fiscal year 2021
were James Hippel, Kim Kelderman, Brenda Furlow, and David Eansor. |
| (11) |
As of June 30, 2023, relates to the time-vesting
restricted share units that were granted in fiscal year 2023. The threshold for the performance-vesting awards was not achieved. |
|
|
|
|
|
|
| Company Selected Measure Name |
|
|
|
organic revenue
|
|
|
|
|
|
| Named Executive Officers, Footnote [Text Block] |
|
|
|
| (1) |
The Company had
two CEOs during fiscal year 2024. Effective November 1, 2023, Mr. Kelderman was appointed the role of Chief Operating Officer
and assumed the role of Chief Executive Officer on February 1, 2024. Mr. Kummeth left his position as Chief Executive Officer
effective February 1, 2024 and remained with the company as a Senior Advisor through July 1, 2024. Mr. Kummeth was our CEO
for the full fiscal years 2021 through 2023. |
|
|
|
|
|
|
| Peer Group Issuers, Footnote |
|
|
|
The Peer Group TSR in
the table utilizes the S&P 500 LifeSciences Tools and Services (“S&P 500 LifeSciences”) Index, which the
company also utilizes in the stock performance graph required by Item 201(e) of Regulation S-K included in the fiscal year
2024 Form 10-K. The comparison assumes $100 (including reinvested dividends) was invested for the period starting June 30,
2020 through June 30, 2024 in the company and in the S&P 500 LifeSciences Index, respectively. Historical stock performance
is not necessarily indicative of future stock performance.
|
|
|
|
|
|
| PEO Total Compensation Amount |
[1] |
|
|
|
|
$ 30,584,644
|
|
$ 15,370,549
|
$ 15,889,896
|
| PEO Actually Paid Compensation Amount |
[1] |
|
|
|
|
4,684,176
|
|
(6,349,624)
|
105,676,083
|
| Adjustment To PEO Compensation, Footnote |
|
|
|
| |
|
|
FY24 |
|
FY23 |
|
|
FY22 |
|
FY21 |
|
| |
|
|
CEO
Mr. Kelderman |
|
|
CEO
Mr. Kummeth |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
| |
Total
from Summary Compensation Table(i)
|
|
|
6,852,495 |
|
|
|
6,792,945 |
|
|
|
12,300,286 |
|
|
|
30,584,644 |
|
|
|
2,258,387 |
|
|
|
15,370,549 |
|
|
|
3,223,063 |
|
|
|
15,889,896 |
|
|
|
4,950,600 |
|
| |
Subtract:
Grant date fair value of option and stock awards granted in the fiscal year(ii) |
|
|
(5,793,851 |
) |
|
|
(5,000,028 |
) |
|
|
(9,849,980 |
) |
|
|
(29,325,210 |
) |
|
|
(850,075 |
) |
|
|
(10,299,362 |
) |
|
|
(949,840 |
) |
|
|
(11,199,803 |
|
|
|
(1,722,395 |
) |
| |
Add:
Fair value at fiscal year end of outstanding and unvested option and stock awards granted in the fiscal year(iii) |
|
|
2,344,977 |
|
|
|
4,234,157 |
|
|
|
2,565,518 |
|
|
|
4,318,227 |
(11) |
|
|
1,382,025 |
|
|
|
6,472,546 |
|
|
|
1,106,688 |
|
|
|
30,362,017 |
|
|
|
10,602,750 |
|
| |
Add/Subtract:
Year-over-Year change in fair value of outstanding and unvested option and stock awards granted in prior fiscal years(iv) |
|
|
— |
|
|
|
(1,241,718 |
) |
|
|
(847,318 |
) |
|
|
(6,132,401 |
) |
|
|
(877,492 |
) |
|
|
(22,021,635 |
) |
|
|
(5,636,997 |
) |
|
|
64,935,446 |
|
|
|
11,789,651 |
|
| |
Add:
Vesting date fair value of option and stock awards granted and vesting during the fiscal year(v) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| |
Add/Subtract:
Change as of the vesting date (from the end of the prior fiscal year) in fair value of option and stock awards granted in any prior
fiscal year for which vesting conditions were satisfied during the fiscal year, less the fair value (as of end of prior fiscal year)
of prior year awards that failed to vest(vi) |
|
|
— |
|
|
|
36,468 |
|
|
|
(20,867 |
) |
|
|
5,238,918 |
|
|
|
633,346 |
|
|
|
4,128,278 |
|
|
|
469,566 |
|
|
|
5,688,527 |
|
|
|
823,785 |
|
| |
|
|
FY24 |
|
FY23 |
|
|
FY22 |
|
FY21 |
|
| |
|
|
CEO
Mr. Kelderman |
|
|
CEO
Mr. Kummeth |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
| |
Subtract:
Awards granted in prior years that did not meet the applicable vesting conditions during the fiscal year(vii) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(121,511 |
) |
|
|
— |
|
|
|
(892,961 |
) |
|
|
— |
|
|
|
— |
|
| |
Compensation Actually
Paid |
|
|
3,403,621 |
|
|
|
4,821,823 |
|
|
|
4,147,638 |
|
|
|
4,684,176 |
|
|
|
2,424,680 |
|
|
|
(6,349,624 |
) |
|
|
(2,680,481 |
) |
|
|
105,676,083 |
|
|
|
26,444,391 |
|
|
|
|
|
|
|
| Non-PEO NEO Average Total Compensation Amount |
[1],[2] |
|
|
$ 12,300,286
|
|
2,258,387
|
|
3,223,063
|
4,950,600
|
| Non-PEO NEO Average Compensation Actually Paid Amount |
[2] |
|
|
$ 4,147,638
|
|
2,424,680
|
|
(2,680,481)
|
26,444,391
|
| Adjustment to Non-PEO NEO Compensation Footnote |
|
|
|
| |
|
|
FY24 |
|
FY23 |
|
|
FY22 |
|
FY21 |
|
| |
|
|
CEO
Mr. Kelderman |
|
|
CEO
Mr. Kummeth |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
| |
Total
from Summary Compensation Table(i)
|
|
|
6,852,495 |
|
|
|
6,792,945 |
|
|
|
12,300,286 |
|
|
|
30,584,644 |
|
|
|
2,258,387 |
|
|
|
15,370,549 |
|
|
|
3,223,063 |
|
|
|
15,889,896 |
|
|
|
4,950,600 |
|
| |
Subtract:
Grant date fair value of option and stock awards granted in the fiscal year(ii) |
|
|
(5,793,851 |
) |
|
|
(5,000,028 |
) |
|
|
(9,849,980 |
) |
|
|
(29,325,210 |
) |
|
|
(850,075 |
) |
|
|
(10,299,362 |
) |
|
|
(949,840 |
) |
|
|
(11,199,803 |
|
|
|
(1,722,395 |
) |
| |
Add:
Fair value at fiscal year end of outstanding and unvested option and stock awards granted in the fiscal year(iii) |
|
|
2,344,977 |
|
|
|
4,234,157 |
|
|
|
2,565,518 |
|
|
|
4,318,227 |
(11) |
|
|
1,382,025 |
|
|
|
6,472,546 |
|
|
|
1,106,688 |
|
|
|
30,362,017 |
|
|
|
10,602,750 |
|
| |
Add/Subtract:
Year-over-Year change in fair value of outstanding and unvested option and stock awards granted in prior fiscal years(iv) |
|
|
— |
|
|
|
(1,241,718 |
) |
|
|
(847,318 |
) |
|
|
(6,132,401 |
) |
|
|
(877,492 |
) |
|
|
(22,021,635 |
) |
|
|
(5,636,997 |
) |
|
|
64,935,446 |
|
|
|
11,789,651 |
|
| |
Add:
Vesting date fair value of option and stock awards granted and vesting during the fiscal year(v) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| |
Add/Subtract:
Change as of the vesting date (from the end of the prior fiscal year) in fair value of option and stock awards granted in any prior
fiscal year for which vesting conditions were satisfied during the fiscal year, less the fair value (as of end of prior fiscal year)
of prior year awards that failed to vest(vi) |
|
|
— |
|
|
|
36,468 |
|
|
|
(20,867 |
) |
|
|
5,238,918 |
|
|
|
633,346 |
|
|
|
4,128,278 |
|
|
|
469,566 |
|
|
|
5,688,527 |
|
|
|
823,785 |
|
| |
|
|
FY24 |
|
FY23 |
|
|
FY22 |
|
FY21 |
|
| |
|
|
CEO
Mr. Kelderman |
|
|
CEO
Mr. Kummeth |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
|
CEO |
|
|
Non-PEO
NEOs |
|
| |
Subtract:
Awards granted in prior years that did not meet the applicable vesting conditions during the fiscal year(vii) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(121,511 |
) |
|
|
— |
|
|
|
(892,961 |
) |
|
|
— |
|
|
|
— |
|
| |
Compensation Actually
Paid |
|
|
3,403,621 |
|
|
|
4,821,823 |
|
|
|
4,147,638 |
|
|
|
4,684,176 |
|
|
|
2,424,680 |
|
|
|
(6,349,624 |
) |
|
|
(2,680,481 |
) |
|
|
105,676,083 |
|
|
|
26,444,391 |
|
|
|
|
|
|
|
| Compensation Actually Paid vs. Total Shareholder Return |
|
|
|
|
|
|
|
|
|
| Compensation Actually Paid vs. Net Income |
|
|
|
|
|
|
|
|
|
| Compensation Actually Paid vs. Company Selected Measure |
|
|
|
|
|
|
|
|
|
| Total Shareholder Return Vs Peer Group |
|
|
|
|
|
|
|
|
|
| Total Shareholder Return Amount |
|
|
|
$ 110.17
|
|
124.96
|
|
132.17
|
171.17
|
| Peer Group Total Shareholder Return Amount |
[3] |
|
|
131.47
|
|
126.72
|
|
129.72
|
147.61
|
| Net Income (Loss) Attributable to Parent |
[4] |
|
|
$ 168,105,000
|
|
$ 285,442,000
|
|
$ 263,099,000
|
$ 139,585,000
|
| Company Selected Measure Amount |
[5] |
|
|
1,141,700
|
|
1,134,700
|
|
1,113,600
|
915,900
|
| Measure [Axis]: 1 |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Measure Name |
|
|
|
Organic Revenue Growth
|
|
|
|
|
|
| Measure [Axis]: 2 |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Measure Name |
|
|
|
Adjusted
Net Income
|
|
|
|
|
|
| Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] | Non-PEO NEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[6] |
|
|
$ (9,849,980)
|
|
$ (850,075)
|
|
$ (949,840)
|
$ (1,722,395)
|
| Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] | PEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[6] |
|
|
|
|
(29,325,210)
|
|
(10,299,362)
|
(11,199,803)
|
| Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] | Non-PEO NEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[7] |
|
|
2,565,518
|
|
1,382,025
|
|
1,106,688
|
10,602,750
|
| Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] | PEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[7] |
|
|
|
|
4,318,227
|
[8] |
6,472,546
|
30,362,017
|
| Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] | Non-PEO NEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[9] |
|
|
(847,318)
|
|
(877,492)
|
|
(5,636,997)
|
11,789,651
|
| Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] | PEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[9] |
|
|
|
|
(6,132,401)
|
|
(22,021,635)
|
64,935,446
|
| Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[10] |
|
|
|
|
|
|
|
|
| Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] | PEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[10] |
|
|
|
|
|
|
|
|
| Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[11] |
|
|
(20,867)
|
|
633,346
|
|
469,566
|
823,785
|
| Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] | PEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[11] |
|
|
|
|
5,238,918
|
|
4,128,278
|
5,688,527
|
| Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] | Non-PEO NEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[12] |
|
|
|
|
(121,511)
|
|
(892,961)
|
|
| Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] | PEO [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[12] |
|
|
|
|
|
|
|
|
| Mr Kelderman [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| PEO Total Compensation Amount |
[2],[13] |
|
|
6,852,495
|
[1] |
0
|
|
0
|
0
|
| PEO Actually Paid Compensation Amount |
[2],[13],[14] |
|
|
3,403,621
|
[1] |
0
|
|
0
|
0
|
| PEO Name |
|
Mr. Kelderman
|
|
|
|
|
|
|
|
| Mr Kelderman [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[6] |
|
|
(5,793,851)
|
|
|
|
|
|
| Mr Kelderman [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[7] |
|
|
2,344,977
|
|
|
|
|
|
| Mr Kelderman [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[9] |
|
|
|
|
|
|
|
|
| Mr Kelderman [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[10] |
|
|
|
|
|
|
|
|
| Mr Kelderman [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[11] |
|
|
|
|
|
|
|
|
| Mr Kelderman [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[12] |
|
|
|
|
|
|
|
|
| Mr Kummeth [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| PEO Total Compensation Amount |
[13] |
|
|
6,792,945
|
[1] |
30,584,644
|
|
15,370,549
|
15,889,896
|
| PEO Actually Paid Compensation Amount |
[13],[14] |
|
|
4,821,823
|
[1] |
$ 4,684,176
|
|
$ (6,349,624)
|
$ 105,676,083
|
| PEO Name |
|
|
Mr. Kummeth
|
|
|
Mr. Kummeth
|
|
Mr. Kummeth
|
Mr. Kummeth
|
| Mr Kummeth [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[6] |
|
|
(5,000,028)
|
|
|
|
|
|
| Mr Kummeth [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[7] |
|
|
4,234,157
|
|
|
|
|
|
| Mr Kummeth [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[9] |
|
|
(1,241,718)
|
|
|
|
|
|
| Mr Kummeth [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[10] |
|
|
|
|
|
|
|
|
| Mr Kummeth [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[11] |
|
|
36,468
|
|
|
|
|
|
| Mr Kummeth [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] |
|
|
|
|
|
|
|
|
|
| Pay vs Performance Disclosure [Table] |
|
|
|
|
|
|
|
|
|
| Adjustment to Compensation Amount |
[12] |
|
|
|
|
|
|
|
|
|
|